CAJ | 학술논문

目的：探讨CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2在三阴性乳腺癌中的表达。方法采用免疫组化方法检测10例三阴性乳腺癌和15例非三阴性乳腺癌标本的CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2的表达状态,并分析两组患者表达结果的差异。所有患者均经免疫组化明确ER、PR、Her-2状态。结果10例三阴性乳腺癌患者中CK5/6阳性4例,CK14阳性4例,CK17阳性2例,EGFR阳性3例,BRCA1阳性3例,BRCA2阳性5例。三阴性与非三阴性乳腺癌在CK5/6和CK14的表达差异有显著性。将三阴性乳腺癌患者中CK5/6、CK14、CK17或EGFR有一个阳性患者分为Basal-like组,其他均为非Basal-like组,则两组患者中CK5/6、CK14、CK17的表达差异有显著性；EGFR的表达差异有显著性。结论 CK5/6和CK14在三阴性乳腺癌中高表达；CK17与EGFR在基底样细胞乳腺癌中高表达；BRCA1、BRCA2与三阴性乳腺癌关系用免疫组化方法尚难判定。
목적：탐토CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2재삼음성유선암중적표체。방법채용면역조화방법검측10례삼음성유선암화15례비삼음성유선암표본적CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2적표체상태,병분석량조환자표체결과적차이。소유환자균경면역조화명학ER、PR、Her-2상태。결과10례삼음성유선암환자중CK5/6양성4례,CK14양성4례,CK17양성2례,EGFR양성3례,BRCA1양성3례,BRCA2양성5례。삼음성여비삼음성유선암재CK5/6화CK14적표체차이유현저성。장삼음성유선암환자중CK5/6、CK14、CK17혹EGFR유일개양성환자분위Basal-like조,기타균위비Basal-like조,칙량조환자중CK5/6、CK14、CK17적표체차이유현저성；EGFR적표체차이유현저성。결론 CK5/6화CK14재삼음성유선암중고표체；CK17여EGFR재기저양세포유선암중고표체；BRCA1、BRCA2여삼음성유선암관계용면역조화방법상난판정。
Objective To study the status of CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2 in triple negative breast cancer. Method The status of CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2 in 10 triple negative breast cancer pa-tients and 15 non-triple negative breast cancer patients were determined by immunohistochemistry. The difference of triple and non-triple negative breast cancer was analyzed. The status of ER,PR,and HER-2 in all cases was confirmed by immunohistochemistry. Result 4 positive CK5/6,4 positive CK14,2 positive CK17,3 positive EGFR,3 positive BRCA1,5 positive BRCA2 in 10 triple-negative breast cancer patients. The status of CK5/6 and CK14 in triple and non-triple negative breast cancer was different. The triple-negative breast cancer patients, who have one of positive status in CK5/6,CK14,CK17 or EGFR, were belong to Basal-like group, and the other breast cancer patients were belong to non Basal-like group. The status of CK5/6,CK14 and CK17 in the two groups was significant different,and the status of EGFR in the two groups was different in static. Conclusion There are high expressions of CK5/6 and CK14 in triple negative breast cancer ;there are high expressions of CK17 and EGFR in Basal-like breast cancer ;and the statuses of BRCA1 and BRCA2 in triple negative breast cancer are not confirmed by immunohistochemistry.